A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
- Primary Progressive Multiple Sclerosis
- Primary Progressive MS
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive MS (SPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Secondary Progressive MS
- Non-Active SPMS
- Non-Active Secondary Progressive Multiple Sclerosis
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Sundance Biosciences, Inc.
- Enrolment target
- 20
- Started
- October 2026
- Main results due
- June 2027
- Study sites
- 3
- Registry updated
- 25 September 2026
Can you take part?
- Ages 18 years to 70 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Aged 18-70, inclusive 2. Diagnosis of PPMS or non-active SPMS 3. No MS relapses in the past 2 years 4. Evidence that MS has continued to get worse over time 5. A level of disability that fits the study requirements Exclusion Criteria: 1. Use of certain medications or treatments before the study, or need for these treatments during the study 2. Current participation in another research study 3. Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk 4. Certain serious or unstable medical conditions that could make the study unsafe 5. Active infection, recent infection, or a history of repeated infections Additional inclusion and exclusion criteria are outlined in the full study protocol.
What this study is about
In the sponsor’s own words, from the registry.
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
Study sites(3)
Local Institution - Site 102
Atlanta, Georgia, United States
Recruiting
Local Institution - Site 101
Raleigh, North Carolina, United States
Recruiting
Local Institution - Site 104
Columbus, Ohio, United States
Recruiting
Showing 3 of 3 sites. 3 of the 3 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07840326. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me